APPARENT REDUCED ABSORPTION OF GEMFIBROZIL WHEN GIVEN WITH COLESTIPOL

被引:14
作者
FORLAND, SC
FENG, Y
CUTLER, RE
机构
[1] JERRY L PETTIS MEM VET ADM MED CTR,11201 BENTON ST,LOMA LINDA,CA 92357
[2] LOMA LINDA UNIV,SCH MED,CLIN PHARMACOL SECT,LOMA LINDA,CA 92354
[3] LOMA LINDA UNIV,SCH MED,NEPHROL SECT,LOMA LINDA,CA 92354
关键词
D O I
10.1002/j.1552-4604.1990.tb03434.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Colestipol and gemfibrozil may be used in combination to lower serum cholesterol and triglycerides. Since colestipol is known to bind certain anionic drugs, we studied the effect of colestipol on the pharmacokinetics of gemfibrozil in 10 patients with elevated serum cholesterol and triglycerides. Each patient received 600 mg of gemfibrozil by mouth during four different studies. Gemfibrozil was given randomly either alone, with, 2 hours before, or 2 hours after 5 grams of colestipol. The serum gemfibrozil concentration time curves were similar when gemfibrozil was given alone or two hours before or after colestipol. There was also no statistical difference in peak gemfibrozil concentration (Cmax), time to Cmax (tmax), area under the curve (AUC), or serum elimination half‐life (t1/2) between any of these three treatments. However, when colestipol was given with gemfibrozil, there was a decrease in AUC (43.6 ± 21.9 mg*hr/L) compared with gemfibrozil given alone (62.6 ± 10.3 mg*hr/L) which was statistically different by both ANOVA and paired t‐test. This finding suggests a decrease in gemfibrozil bioavailability. Cmax when colestipol was given with gemfibrozil (14.7 ± 6.6 mg/L) was not statistically different from gemfibrozil alone (20.1 ± 4.9 mg/L). However, the mean serum concentrations when gemfibrozil was given with colestipol were significantly lower at the 0.5, 1.0 and 1.5 hour sampling times when compared to the other regimens. Gemfibrozil serum elimination half‐life was not significantly altered by combination with colestipol. The data suggest a reduction of gemfibrozil bioavailability when colestipol is administered concomitantly. Separating the administration of these two drugs by at least two hours will avoid this drug interaction. 1990 American College of Clinical Pharmacology
引用
收藏
页码:29 / 32
页数:4
相关论文
共 19 条
[1]   INTRINSIC FACTOR-MEDIATED BINDING OF CYANOCOBALAMIN TO CHOLESTYRAMINE [J].
ANDERSEN, KJ ;
SCHJONSBY, H .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1978, 67 (11) :1626-1627
[2]   DIGITALIS INTOXICATION - TREATMENT WITH A NEW STEROID-BINDING RESIN [J].
BAZZANO, G ;
BAZZANO, GS .
JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1972, 220 (06) :828-&
[3]  
BROWN DD, 1978, CIRCULATION, V58, P152
[4]   INTERRUPTION OF ENTEROHEPATIC CIRCULATION OF DIGITOXIN BY CHOLESTYRAMINE .2. EFFECT ON METABOLIC DISPOSITION OF TRITIUM-LABELED DIGITOXIN AND CARDIAC SYSTOLIC INTERVALS IN MAN [J].
CALDWELL, JH ;
BUSH, CA ;
GREENBER.NJ .
JOURNAL OF CLINICAL INVESTIGATION, 1971, 50 (12) :2638-&
[5]   EFFECT OF CHOLESTYRAMINE AND COLESTIPOL ON THE ABSORPTION OF PHENYTOIN [J].
CALLAGHAN, JT ;
TSURU, M ;
HOLTZMAN, JL ;
HUNNINGHAKE, DB .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1983, 24 (05) :675-678
[6]  
DEPAOLIS C, 1986, BRIT J CLIN PHARMACO, V22, P496
[7]   EFFECT OF COLESTIPOL HYDROCHLORIDE ON THE BIOAVAILABILITY AND PHARMACOKINETICS OF CLOFIBRATE [J].
DESANTE, KA ;
DISANTO, AR ;
ALBERT, KS ;
WEBER, DJ ;
WELCH, RD ;
VECCHIO, TJ .
JOURNAL OF CLINICAL PHARMACOLOGY, 1979, 19 (11-1) :721-725
[8]   COMBINATION-DRUG THERAPY FOR FAMILIAL COMBINED HYPERLIPIDEMIA [J].
EAST, C ;
BILHEIMER, DW ;
GRUNDY, SM .
ANNALS OF INTERNAL MEDICINE, 1988, 109 (01) :25-32
[9]  
FARAQUI AMA, 1981, JPMA, V31, P241
[10]  
FORLAND SC, 1987, CLIN CHEM, V33, P1938